Healthpeak Properties (DOC) Q1 2026 earnings review
Janus IPO Unlocks Value, But Lab Trough Drags Core Earnings
Healthpeak completed its highly anticipated Janus Living IPO, capitalizing on surging Senior Housing fundamentals (+13.8% Same-Store NOI). However, core operating metrics reflect the anticipated lab sector trough. While Net Income spiked 356% to $0.28 per share due to transaction gains, FFO as Adjusted slipped to $0.45 from $0.46 a year ago. Total Same-Store NOI flatlined at 0.0%, dragged down entirely by a 7.2% contraction in the Lab segment. Full-year FFO guidance received a slight bump at the midpoint, but the stark divergence between booming senior housing and struggling lab assets defines the quarter.
🐂 Bull Case
The successful spin-out of Janus Living at the high-end of its valuation range raised $880M. Healthpeak retains an 81.6% stake, keeping exposure to the segment's accelerating 13.8% SS NOI growth while gaining an independent capital vehicle.
The largest segment (55.7% of SS NOI) remains a rock-solid anchor, delivering 2.4% SS NOI growth and executing 1.2M sq ft of leases with +5.4% cash re-leasing spreads.
🐻 Bear Case
The lagging impact of 2025's tenant capital failures has hit the income statement. Lab SS NOI collapsed 7.2% YoY, dragging the entire portfolio's SS NOI down to zero.
Despite a 7.1% increase in total revenue, FFO as Adjusted declined 2.5% YoY to $316.8M, reflecting higher refinancing costs and the ongoing lab vacancies.
⚖️ Verdict: ⚪
Neutral. Management successfully executed major structural and capital allocation goals (Janus IPO, Blackstone JV), but the core Life Science operating business remains in an active contraction phase.
Key Themes
Lab Segment Trough Materializes
As guided in previous quarters, the 2025 lab occupancy losses are now fully impacting earnings. Lab Same-Store NOI reversed sharply, falling 7.2% YoY. While management noted that total lab occupancy increased sequentially and is expected to rise through year-end, the near-term financial drag is severe enough to wipe out gains from the rest of the portfolio.
Janus Living IPO Unlocks Senior Housing Value
The IPO of Janus Living (NYSE: JAN) generated $880M in net proceeds, allowing the pure-play senior housing REIT to pursue $400M in new acquisitions. Senior housing is Healthpeak's fastest-growing segment, accelerating to 13.8% SS NOI growth in Q1. By retaining an 81.6% equity stake, Healthpeak benefits from the upside while offloading the capital-intensive acquisition pipeline.
Strategic Joint Ventures for Capital Recycling
Healthpeak continues to capitalize on strong private market demand for outpatient assets. The company sold an 80% interest in a 6-property Outpatient Medical portfolio to Blackstone, generating $170M in proceeds at a highly attractive 6.1% trailing cash cap rate ($508/sq ft). This provides dry powder for share repurchases and lab reinvestment.
Aggressive Share Repurchases
Management is utilizing its liquidity to buy back its own discounted shares. In April 2026, Healthpeak repurchased 5.9 million common shares at an average price of $16.81 for roughly $100M, leaving $306M on the current authorization. This signals confidence that the stock is trading below the intrinsic value of its underlying real estate.
Rising Leverage Profile
Net Debt to Adjusted EBITDAre crept up to 5.4x in Q1 2026, compared to 5.2x at the end of 2025. While still within a healthy range, the slight deterioration in fixed charge coverage and leverage ratios bears monitoring as the company navigates $1.1B in 2026 refinancing activity.
Other KPIs
Stable. The Outpatient Medical segment continues to demonstrate remarkable consistency. Cash re-leasing spreads held strong at 5.4% on 868,000 square feet of renewals, proving that tenant demand remains resilient and pricing power is intact despite macro volatility.
Decelerating. Cash re-leasing spreads in the Lab segment compressed to 3.5% (down from 5.0% in Q1 2025 and 6.0% in mid-2025). This reflects the loss of landlord pricing power amid a highly competitive market burdened by excess supply and cautious tenant capital.
Guidance
Decelerating. Management slightly raised the bottom end of the range (previously $1.70 - $1.74). However, the midpoint of $1.73 still represents a roughly 6% decline compared to FY25's $1.84, confirming that 2026 is an earnings trough year.
Decelerating. Reaffirmed guidance. This stagnant growth profile highlights the severe drag from the Lab segment, completely offsetting the double-digit growth seen in the Senior Housing portfolio.
Key Questions
Lab Segment Inflection Point
Lab Same-Store NOI fell 7.2% YoY, but occupancy increased sequentially. At what point in late 2026 or early 2027 do you expect Same-Store NOI to inflect back to positive growth?
Janus Living Acquisition Pipeline
Janus Living has $400M in senior housing acquisitions under contract. In the current interest rate environment, what are the target going-in yields and stabilized yields for these new assets?
Blackstone JV Strategy
The recapitalization with Blackstone was executed at an attractive 6.1% cap rate. Is this a one-off transaction, or the beginning of a larger programmatic shift to move stabilized Outpatient Medical assets into private joint ventures?
Leverage Tolerance
Net Debt to Adjusted EBITDAre ticked up to 5.4x. Given the $1.1B in refinancing needs for 2026, what is your upper limit for leverage before you pause share repurchases?